RCUSArcus Biosciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Rangebound, no clear trend. Price is −0% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RCUS is trading
Arcus Biosciences, Inc. is +97% over the past year while the S&P 500 is +18%: 79 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −0.17%
vs 200-day average · below trend, but not far
- RSI (14)
- 40
RSI (14) · neutral
- Below its 52-week high
- 23%
Below its 52-week high
Details›
- Last close2026-10-09
- $24.39
- 1 monthS&P 500 +2.7%
- −6.7%
- 1 yearS&P 500 +18%
- +97%
- 5 yearsS&P 500 +88%
- −26%
- vs 50-day average$27.40
- −11%
- 52-week high
- $31.57
- 52-week low
- $12.37
- Annualised volatility
- 61%
| Year | Return |
|---|---|
| 2026 (year to date) | +2.3% |
| 2025 | +60% |
| 2024 | −22% |
| 2023 | −7.6% |
| 2022 | −49% |
| 2021 | +56% |
| 2020 | +157% |
| 2019 | −6.2% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 2 of 8 | −6.2% |
| Feb | 8 | 5 of 8 | +13% |
| Mar | 8 | 3 of 8 | −7.7% |
| Apr | 9 | 4 of 9 | +8.0% |
| May | 9 | 4 of 9 | −2.5% |
| Jun | 9 | 4 of 9 | +0.48% |
| Jul | 9 | 4 of 9 | +0.15% |
| Aug | 9 | 6 of 9 | +6.4% |
| Sep | 9 | 4 of 9 | +0.80% |
| Oct | 9 | 3 of 9 | +0.63% |
| Nov | 8 | 7 of 8 | +18% |
| Dec | 8 | 2 of 8 | −2.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.